Non-small cell lung cancer (NSCLC, KRAS G12C-mutated)
- Treat first-line according to standard NSCLC context
- KRAS G12C inhibitor is a targeted option after prior therapy
- Sotorasib/adagrasib-class drugs target the mutant pocket
- CNS activity and toxicity differ by agent
- Check CYP/acid-suppression interactions by product
- Resistance commonly develops
Use at a glance
- Treat first-line according to standard NSCLC context
Treatment options
- KRAS G12C inhibitor is a targeted option after prior therapy
Other treatment options
- Sotorasib/adagrasib-class drugs target the mutant pocket
- Resistance commonly develops
Practical pearls
- CNS activity and toxicity differ by agent
- Check CYP/acid-suppression interactions by product
Self-check
- Which product-specific interactions are checked with KRAS G12C inhibitors?
CYP/acid-suppression interactions by product. - When is a KRAS G12C inhibitor a targeted option in NSCLC?
After prior therapy.
Drugs used for this (1)
All clinical uses · Open Non-small cell lung cancer (NSCLC, KRAS G12C-mutated) in the interactive console ↗